If the U.S. wants to save lives, it should take notes from how other countries regulate e-cigarettes. Read this piece from Real Clear Health to learn why.
Congress is looking for a solution in search of a problem. Read this article in Inside Sources to learn why: Congressional Misstep Could Undermine Patient Access, Trust in New Drugs
July 23, 2019 Dear Chairman Grassley and Ranking Member Wyden, As organizations representing American consumers, seniors, taxpayers, and free-market advocates, we are writing to express concerns over Section 207 of S. 1895, the Lower Health Care Costs Act. Many provisions of the bill would expand consumer choice, save taxpayer money, and lower out-of-pocket costs for […]
A draft of the Lower Health Care Costs Act circulated by the U.S. Senate’s powerful Health, Education, Labor, and Pensions Committee includes a provision that would drastically change how the U.S. develops standards for the strength, quality, and purity of medicines, particularly cutting-edge biologics and biosimilars. Read this op-ed at The Hill to learn why […]
A coalition of nonprofit think tanks sent a letter to FDA Commissioner Sharpless urging reforms to current regulatory regulations that are impeding market competition between drug makers. The letter states that increasing market competition is the best means for price reductions, which will lower medical program costs, taxpayer burdens, and out-of-pocket expenses for consumers, as […]
Today, the American Consumer Institute Center for Citizen Research (ACI) announced the release of its latest ConsumerGram, highlighting the promise of new gene replacement therapies and urging health care stakeholders to develop innovative ways of financing these important treatments. The report, authored by Dr. Joseph Fuhr, Liam Sigaud and Steve Pociask, describes the economic benefits […]
A group of 29 nonprofit organizations filed a letter with the FDA calling on them to foster the development of a robust biosimilars market, which would ultimately reduce prescription drug costs and provide patients with access to more affordable therapies. The letter is available online.
Laboratory Developed Tests (LDTs) have become a source of convenience and hope for patients, but they have also triggered controversy about the safety of their impact on consumer expectations, and about the accuracy of the clinical results they provide. In 2014, the Food and Drug Administration (FDA) and the Centers for Medicare and Medicaid Services […]
For consumers, personal sound amplification devices can boost sound that is too faint for most of us to hear. This technology can be used by consumers who want to temporarily heighten their hearing, including the use of headphones and equipment used to modestly boost the sound on telephones, listening devices and other audio amplification, and […]
Today, ACI joined a broad coalition of nonprofit groups in opposition to a Congressional proposal to give the FDA authority to regulate over-the-counter personal sound application devices sold in many stores, including Best Buy, Walmart and others. These regulations would do little to benefit consumers, but would certainly lead to significantly higher consumer prices. Download the Letter.